Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gum disease breakthrough? blood concentrate shows promise in small trial

NCT ID NCT07375004

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding injectable Platelet-Rich Fibrin (i-PRF), a natural concentrate from a patient's own blood, to standard deep cleaning improves gum disease outcomes. In 13 adults with moderate to severe periodontitis, one side of the mouth received the combined treatment and the other side standard cleaning alone. Researchers measured pocket depth, gum attachment, and bacterial levels over 3 months to see if i-PRF provides extra benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Nov 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects aged 30 years and above. * No history of systemic diseases (e.g., diabetes mellitus). * Not currently under active periodontal therapy or joining other trial in the last 3 months. * Diagnosis with Stage II or III Periodontitis. * presence of interdental CAL affecting ≥2 non adjacent teeth or if CAL at buccal/lingual aspects associated with PPD \>4mm at ≥2 teeth. Exclusion Criteria: * Smokers or alcohol users. * Patients consuming antibiotics or anticoagulants. * Regular users of non-steroidal anti-inflammatory drugs. * Receipt of periodontal treatment within 3 months prior to the study. * Any bleeding or clotting disorders. * Teeth with Grade II or Grade III furcation involvement. * Pregnant or breastfeeding mothers. * Patients unwilling to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar bone loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mustansiriyah University, College of Dentistry.

    Baghdad, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.